CTS Retina

In this podcast, expert clinicians will discuss ongoing clinical trials and the latest data regarding advances in vitreoretinal care: https://lnkd.in/dz_VebRT

CTS2024 took place two months ago, but the exciting update is that CTS 2025 is only 10 months away! Let's reminisce about CTS 2024 and the remarkable Champions of Retina Clinical Research. #CTS2024 Arshad M. Khanani Jeff Heier Peter Kaiser David Boyer, MD Diana Do Frank G. Holz Anat Loewenstein SriniVas Sadda Ramin Tadayoni

A phase 3 program will investigate bel-sar delivered through a suprachoroidal injection and activated with a laser in patients with #choroidalmelanoma. J. Jill Hopkins, MD, of Aura Biosciences discusses the program 👇 #OcularSurgeryNews #CTSRetina CTS Retina https://lnkd.in/e7z5AwdX

CTS Retina coverage continues! In the The SUMMIT study, the port delivery system showed a real-world maintenance of #visualacuity and central subfield thickness, as well as a well-tolerated safety profile, in patients with neovascular #AMD. Arshad M. Khanani, MD, MA, FASRS, discussed the details with Healio 👇 #OcularSurgeryNews #Retina Genentech https://lnkd.in/ePyMfG42

It’s been an exciting week for our colleagues at Genentech - after two years, #Susvimo makes a comeback! Carlos Quezada Ruiz provided this update at the #CTS2024 meeting.

🚨ICYMI🚨 Charles Semba (仙波), MD, of Eluminex Biosciences Limited, discussed EB-105, trispecific antibody for #DME that targets VEGF-A, VEGF-B, placental growth factor, angiopoietin-2 and interleukin-6 receptor, at #CTS_Retina. “We hope the combination of these three [moieties] will present an incremental breakthrough to really address the difficult nature in treating residual fluid in patients with #diabeticeyedisease,” he said. Full Healio 📽 below. #OcularSurgeryNews CTS Retina #Ophthalmology #Retina https://lnkd.in/e9HiYQa9

Ixo-vec has shown promise in reducing the number of #aflibercept injections in neovascular #AMD. Adam Turpcu, PhD, of Adverum Biotechnologies discussed the #genetherapy with Healio at CTS Retina. 🔗 #OcularSurgeryNews #Retina https://lnkd.in/eeBdQpKG

Ramanath Bhandari, MD, FASRS, of RevOpsis Therapeutics discusses the development of RO-104 for the treatment of retinal disease. 🔗 below #OcularSurgeryNews #Retina #CTS_Retina CTS Retina https://lnkd.in/ecHWeJTp

A phase 3 trial of elamipretid for #dryAMD is targeting the new #FDA-approved endpoint of photoreceptor protection. Reenie McCarthy of Stealth BioTherapeutics spoke with Healio about the details 🔗 #ocularSurgeryNews #CTS_Retina CTS Retina https://lnkd.in/eX5G5VKn

4D-150 demonstrated positive safety, retinal anatomy and durability results, as well as a reduction in the need for annualized anti-VEGF injections in patients with wet #AMD, in the PRISM phase 2 clinical trial. The company has also filed an investigational new drug application for 4D-175 for the treatment of #geographicatrophy. David Kirn, MD, of 4D Molecular Therapeutics spoke with Healio at CTS Retina 🔗 #OcularSurgeryNews #ophthalmology #CTSRetina #Retina https://lnkd.in/ehKwBDpq